

Please fax both pages of completed form to your team at 888.355.6682.

To reach your team, call toll-free 877.218.0410.

You can now monitor shipments and chat online if you have questions. Go to MyAccredoPatients.com to log in or get started.

## Prescription & Enrollment Form Adult Growth Disorders

accredo<sup>®</sup>

### Four simple steps to submit your referral.

## 1 Patient Information



Please attach copies of front and back of the patient's medical and prescription insurance cards.

New patient  Current patient

Patient's first name \_\_\_\_\_ Last name \_\_\_\_\_ Middle initial \_\_\_\_\_

Male  Female Last 4 digits of SSN \_\_\_\_\_ Date of birth \_\_\_\_\_

Street address \_\_\_\_\_ Apt # \_\_\_\_\_

City \_\_\_\_\_ State \_\_\_\_\_ Zip \_\_\_\_\_

Home phone \_\_\_\_\_ Cell phone \_\_\_\_\_ E-mail address \_\_\_\_\_

Parent/guardian (if applicable) \_\_\_\_\_

Home phone \_\_\_\_\_ Cell phone \_\_\_\_\_ E-mail address \_\_\_\_\_

Alternate caregiver/contact \_\_\_\_\_

Home phone \_\_\_\_\_ Cell phone \_\_\_\_\_ E-mail address \_\_\_\_\_

OK to leave message with alternate caregiver/contact

Patient's primary language:  English  Other If other, please specify \_\_\_\_\_

## 2 Prescriber Information

All fields must be completed to expedite prescription fulfillment.

Date \_\_\_\_\_ Time \_\_\_\_\_ Date medication needed \_\_\_\_\_

Prescriber's first name \_\_\_\_\_ Last name \_\_\_\_\_

Prescriber's title \_\_\_\_\_ If NP or PA, under direction of Dr. \_\_\_\_\_

Office address \_\_\_\_\_

Office contact and title \_\_\_\_\_

Office contact phone number \_\_\_\_\_ Office contact e-mail \_\_\_\_\_

Office/Infusion clinic name \_\_\_\_\_ Office/Infusion clinic affiliation \_\_\_\_\_

Street address \_\_\_\_\_ Suite # \_\_\_\_\_

City \_\_\_\_\_ State \_\_\_\_\_ Zip \_\_\_\_\_

Phone \_\_\_\_\_ Fax \_\_\_\_\_ NPI # \_\_\_\_\_ License # \_\_\_\_\_

Deliver product to:  Office  Patient's home  Clinic Clinic location: \_\_\_\_\_

## 3 Clinical Information

Primary ICD-10 code: \_\_\_\_\_ Weight (kg) \_\_\_\_\_ Height (cm) \_\_\_\_\_ Date measured \_\_\_\_\_

Injection training needed:  Yes  No By:  MD office  Other \_\_\_\_\_

If prior HgH used, date started \_\_\_\_\_

NKDA  Known drug allergies \_\_\_\_\_

Concurrent meds \_\_\_\_\_

Please attach the following information for growth disorder diagnosis: Drug profile, labs, growth chart where applicable

Patient's first name \_\_\_\_\_ Last name \_\_\_\_\_ Middle initial \_\_\_\_\_ Date of birth \_\_\_\_\_

Prescriber's first name \_\_\_\_\_ Last name \_\_\_\_\_ Phone \_\_\_\_\_

## 4 Prescribing Information

Medication	Dose	Directions	Quantity/Refills
<input type="checkbox"/> Genotropin® (somatropin) cartridge	<input type="checkbox"/> 5mg <input type="checkbox"/> 12mg		Dispense: <input type="checkbox"/> 1-month supply <input type="checkbox"/> 3-month supply <input type="checkbox"/> Other _____ _____ <input type="checkbox"/> Refills _____
<input type="checkbox"/> Genotropin (somatropin) Mini Quick® (somatropin) cartridge	<input type="checkbox"/> 0.2mg <input type="checkbox"/> 0.4mg <input type="checkbox"/> 0.6mg <input type="checkbox"/> 0.8mg <input type="checkbox"/> 1mg <input type="checkbox"/> 1.2mg <input type="checkbox"/> 1.4mg <input type="checkbox"/> 1.6mg <input type="checkbox"/> 1.8mg <input type="checkbox"/> 2mg		
<input type="checkbox"/> Humatrope® (somatropin) 5mg vial			
<input type="checkbox"/> Humatrope (somatropin) cartridge	<input type="checkbox"/> 6mg <input type="checkbox"/> 12mg <input type="checkbox"/> 24mg		
<input type="checkbox"/> HumatroPen® (somatropin) injection device for cartridge	<input type="checkbox"/> 6mg <input type="checkbox"/> 12mg <input type="checkbox"/> 24mg		
<input type="checkbox"/> Increlex® (mecasermin) 40mg/4mL vial			
<input type="checkbox"/> Norditropin® (somatropin) FlexPro® prefilled pen	<input type="checkbox"/> 5mg <input type="checkbox"/> 10mg <input type="checkbox"/> 15mg <input type="checkbox"/> 30mg		
<input type="checkbox"/> Nutropin (somatropin) AQ Pen® cartridge 20mg/2mL			
<input type="checkbox"/> Nutropin (somatropin) AQ NuSpin® prefilled device	<input type="checkbox"/> 5mg <input type="checkbox"/> 10mg <input type="checkbox"/> 20mg		
<input type="checkbox"/> Omnitrope® (somatropin) 5.8mg vial			
<input type="checkbox"/> Omnitrope (somatropin) cartridge	<input type="checkbox"/> 5mg/1.5mL <input type="checkbox"/> 10mg/1.5mL		
<input type="checkbox"/> Saizen® (somatropin)	<input type="checkbox"/> 5mg vial <input type="checkbox"/> 8.8mg vial <input type="checkbox"/> 8.8mg cartridge		
<input type="checkbox"/> Zomacton® (somatropin)	<input type="checkbox"/> 5mg vial <input type="checkbox"/> 10mg vial		
<input type="checkbox"/> Other _____			
_____			

If shipped to physician's office or infusion clinic, physician accepts on behalf of patient for administration in office or infusion clinic.

I certify that this medication is not being prescribed for anti-aging, cosmetic or athletic performance. I further certify human growth hormone is being prescribed for the medical condition noted above and is medically necessary.

Prescriber's signature (sign below) (Physician attests this is his/her legal signature. NO STAMPS)

### PHYSICIAN SIGNATURE REQUIRED

**SIGN  
HERE**

Date

Dispense as written

Date

Substitution allowed

The prescriber is to comply with his/her state-specific prescription requirements such as e-prescribing, state-specific prescription form, fax language, etc. Non-compliance with state-specific requirements could result in outreach to the prescriber.

**FOR REFERENCE ONLY:** This page is for reference only and should not be returned. Diagnosis must be indicated in section 3 of the enrollment form.

### COMMON DIAGNOSIS CODES

**B20** Human immunodeficiency virus [HIV] disease

With: **R64** Cachexia (Serostim® only)

With: **E88.1** Lipodystrophy (Egrifta® only)

**E23.0** Idiopathic growth hormone deficiency:

• Childhood-onset • Adult-onset

**E34.3** Short stature due to endocrine disorder

**E23.0** Acquired growth hormone deficiency with:

• Childhood-onset • Adult-onset

**C75.1** Malignant neoplasm of pituitary gland

**C75.2** Malignant neoplasm of craniopharyngeal duct

**D35.2** Benign neoplasm of pituitary gland

**D35.3** Benign neoplasm of craniopharyngeal duct

**E23.0** Hypopituitarism

**E23.1** Drug-induced hypopituitarism

**E89.3** Postprocedural hypopituitarism

**E23.3** Hypothalamic dysfunction

**N18.9** Chronic kidney disease (child, pre-transplant):

• HD • CAPD • CCPD, schedule: \_\_\_\_\_

**N18.2** CKD, Stage II (Mild)

**N18.3** CKD, Stage III (Moderate)

**N18.4** CKD, Stage IV (Severe)

**N18.5** CKD, Stage V

**N18.6** End stage renal disease

**Congenital disease & associated disorders:**

**Q96.9** Turner's syndrome

**Q87.1** Noonan syndrome

**Q87.1** Prader-Willi syndrome

**E34.3, Q78.8** SHOX deficiency

**Q87.1** Russell-Silver syndrome

**Q89.8** Other specified congenital malformations

**R62.50** Severe IGF-1 deficiency (Increlex® only)

**R62.52** Small for Gestational Age with inadequate catch-up growth (child):

**P05.10** Small for gestational age

**P05.00** Light for gestational age

**P05.9** Slow intrauterine growth

**R62.52** Idiopathic Short Stature (child) with – 2.25 SDS

**K91.2** Short-bowel Syndrome (Zorbtive® only)